This recent drug trial and editorial click here published in NEJM September 2010 show the outcome of too much analgesia when treating osteoarthritis of the knee. The study drug was Tanezumab, a monoclonal antibody that blocks nerve growth factor which then produces pain relief. Unfortunately the drug was too effective, which caused some patients to wear out their knees so badly they needed knee replacements. Consequently the FDA has put a halt on the studies with Tanezumab.
This recent drug trial and editorial click here published in NEJM September 2010 show the outcome of too much analgesia when treating osteoarthritis of the knee. The study drug was Tanezumab, a monoclonal antibody that blocks nerve growth factor which then produces pain relief. Unfortunately the drug was too effective, which caused some patients to wear out their knees so badly they needed knee replacements. Consequently the FDA has put a halt on the studies with Tanezumab.
Comments
Post a Comment